• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Quintiles Limited - Articles and news items

Biogen Idec logo

Quintiles and Biogen Idec announce comprehensive 
clinical development partnership

Industry news / 24 April 2014 / Biogen Idec

Quintiles and Biogen Idec have entered into a five-year strategic clinical development agreement…

Taking clinical trials into the future

Issue 2 2007, Past issues / 27 March 2007 / EPR

Q1: Please outline the general process of Phase I clinical trials.

Burnand: Phase I is the screening for safety process and it’s the first time that a product is given to a human being. The aim at this stage is to demonstrate that the product isn’t dangerous. The data will alsol be used to determine the dosage for the Phase II stage and we estimate that between 20 – 100 healthy volunteers participate (and in some cases they are not healthy volunteers, where there will be some known side effects, but generally they are healthy).

Integration is key

Issue 2 2006, Past issues / 24 March 2006 / E. Allen, T. Mant, C. Vose: Guy’s Drug Research Unit, Quintiles Limited

Drug development has become more complex and significantly more expensive. There has been an estimated 55% increase in the critical path development costs since the year 20001. More than 50% of these costs are incurred in later phase development (Phase IIb and III studies).

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionWATCH NOW
+ +